Project Grant R01NS125591

Award Date 7/15/24
Completion Date 6/30/29
Dollars Obligated $2.3M
Funding Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Richland, WA 99354, USA
Similar Awards
The National Institute on Aging (NIA) awarded a $405,849 Project Grant (CFDA 93.866 - Aging Research) to the Keck Graduate Institute of Applied Life Sciences to investigate the impact of obesity-induced hepatic amyloid beta dysregulation on Alzheimer's disease pathology. The key objectives are to: Examine the relationship between changes in peripheral and hepatic amyloid beta with brain amyloid beta load and Alzheimer's disease pathology in Alzheimer's disease mice fed a high-fat/high-sugar...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $2,273,637 to The Johns Hopkins University to conduct a comprehensive study of plasma and brain lipidomics (lipid profiling) and their associations with Alzheimer's disease, dementia, and cognitive decline. The study will leverage advanced lipidomics technology to quantify over 1,500 lipid species in plasma samples from 3,868 participants in the Cardiovascular Health Study and postmortem brain...
This $342,934.65 project grant from the Department of Health and Human Services National Institutes of Health National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research into acyl chain remodeling and regional lipid dysregulation in Alzheimer's disease. The Trustees of Columbia University in the City of New York, doing business as Health Sciences Division, will analyze lipid composition in brain regions susceptible to Alzheimer's disease, such as the...
This Project Grant award of $2,683,965.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will fund the development and optimization of an "all-human cellular system" for studying Alzheimer's disease (AD) and age-related dementias (ADRDs). The primary objectives are to: 1) define delivery conditions for introducing patient blood cells and plasma into a...
This $4.2 million project grant from the National Institutes of Health's National Institute on Aging will fund research into the mechanisms by which the ABCA7 gene influences Alzheimer's disease. The Trustees of the University of Pennsylvania will investigate the specific lipid species affected by deletion of ABCA7 in three types of induced pluripotent stem cell-derived brain cells. Researchers will also identify ABCA7 protein domains that differentiate its functions from ABCA1 and...
The National Institute on Aging awarded a $2,250,745 Project Grant (CFDA 93.866 - Aging Research) to Mayo Clinic Jacksonville, doing business as Scott Lynch MD, to conduct research on the role of apolipoprotein E (APOE) in meningeal lymphatic function and its impact on Alzheimer's disease pathophysiology. The research aims to uncover the effects of APOE4 expression on meningeal lymphatic drainage and immune cell interactions, and how this may contribute to neuroinflammation and amyloid-β...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research (CFDA 93.866) federal grant program, aims to develop novel lipid nanoparticle (LNP) formulations for efficient delivery of nucleic acid therapeutics to the brain to treat Alzheimer's disease (AD). The $835,417 award will fund research to synthesize BBB-crossing lipids, formulate LNP-RNA constructs, and evaluate their therapeutic effects, pharmacokinetics, and safety in mouse AD models. The comprehensive...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $454,271 to Florida Atlantic University to investigate the role of amyloid precursor protein (APP) and cholesterol homeostasis in synaptic dysfunction and neurodegeneration related to Alzheimer's disease (AD). The research aims to use human neurons derived from induced pluripotent stem cells (hiNs) to systematically study how mutations affecting APP distribution, trafficking, and interaction...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to The Trustees of Columbia University in the City of New York provides $452,375 to investigate the potential use of the APLP1 protein as an early biomarker for Alzheimer's disease in individuals with Down syndrome. The project aims to leverage recent findings linking endosomal trafficking defects to the early pathology of Alzheimer's disease, which is observed decades before classical...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $3,477,475 to the Icahn School of Medicine at Mount Sinai to investigate the combined role of the APOE4 gene variant and ketogenic diets in the development of Alzheimer's disease (AD). The award will fund a 5-year research study aimed at elucidating the molecular mechanisms by which APOE4 interacts with high-fat/ketogenic diets to exacerbate AD pathogenesis. The research will employ in vitro...

THE IMPACT OF BRAIN LIPOPROTEIN STRUCTURE AND COMPOSITION ON AMYLOID BETA METABOLISM AND ALZHEIMER'S DISEASE - PROJECT SUMMARY/ABSTRACT ALZHEIMER'S DISEASE (AD) IS A DEBILITATING BRAIN DISORDER CHARACTERIZED BY MEMORY LOSS AND COGNITIVE DECLINE, AFFECTING MILLIONS WORLDWIDE. THE INTRICATE INTERPLAY BETWEEN LIPID METABOLISM AND AD PATHOLOGY IS INCREASINGLY RECOGNIZED, AND BRAIN LIPOPROTEINS (BLPS) ARE THOUGHT TO BE KEY PLAYERS GIVEN THEY SERVE AS THE PRIMARY LIPID TRANSPORT VEHICLES IN THE CENTRAL NERVOUS SYSTEM (CNS). BLPS RESIDE IN THE CEREBROSPINAL FLUID (CSF) THAT BATHES THE BRAIN BUT UNFORTUNATELY, DUE TO THEIR LOW ABUNDANCE AND LIMITED ACCESSIBILITY, A COMPREHENSIVE UNDERSTANDING OF BLPS HAS REMAINED ELUSIVE. WE DEVELOPED A FLUORESCENT LIPOPROTEIN PROFILING (FLP) TECHNOLOGY THAT HURDLES THIS ABUNDANCE PROBLEM TO DEEPLY CHARACTERIZE BLPS IN SMALL VOLUMES OF CSF. USING OUR FLP AND MASS SPECTROMETRY (LC-MS/MS), WE REVEALED THAT BLPS CONSIST OF A SPECTRUM OF DISCRETELY SIZED SUBPOPULATIONS THAT EXHIBIT REMARKABLE PROTEOMIC DIVERSITY. WE POSIT THAT THE DOMINANT ORGANIZING SCAFFOLD ON BLPS, APOLIPOPROTEIN (APO)E, ACTS AS A MASTER REGULATOR OF BLP COMPOSITION BY ADOPTING DISTINCT STRUCTURAL CONFORMATIONS TO FACILITATE DOCKING WITH COMPLEMENTARY PARTNERS THAT IMPART UNIQUE FUNCTIONS. APOE HAS THREE ISOFORMS-E2, E3, AND E4 DIFFERENTIATED BY CYSTEINE-ARGININE MUTATIONS AT RESIDUES 112 AND 158 AND CARRIERS OF APOE4 HAVE INCREASED AMYLOID PLAQUE BURDEN, AND SUBSTANTIALLY INCREASED LIFETIME RISK FOR DEVELOPING AD. WE HYPOTHESIZE THAT CONFORMATIONAL DIFFERENCES BETWEEN APOE ISOFORMS ALTER BLP COMPOSITIONAL SIGNATURES AND THEIR ABILITY TO BIND AND TRAFFIC AMYLOID BETA (AB), THE BUILDING BLOCK OF AMYLOID PLAQUES. OUR OBJECTIVES ARE TWO-FOLD: FIRST, TO ASSESS THE IMPACT OF APOE ISOFORMS ON BLP DISTRIBUTION, COMPOSITION, AND ABILITY TO BIND AB. TO DO SO, WE WILL PERFORM A COMPARATIVE ANALYSIS OF BLP PATTERNS IN INDIVIDUALS WITH DIFFERENT APOE GENOTYPES AND LEVELS OF COGNITIVE HEALTH USING OUR FLP AND LC-MS/MS, SHEDDING LIGHT ON THE AD-RELEVANT BLP SUBSPECIES. SECOND, WE AIM TO UNRAVEL THE STRUCTURAL DETAILS OF LIPID-BOUND APOE ISOFORMS THAT GOVERN THEIR INTERACTIONS WITH AB. USING CRYO-EM AND NOVEL STRUCTURAL PROTEOMICS APPROACHES, WE WILL DERIVE HIGH-RESOLUTION STRUCTURAL MAPS OF AB COMPLEXED WITH DIFFERENT APOE ISOFORMS ON RECONSTITUTED HDL AND DETERMINE HOW "ACCESSORY" PROTEINS FOUND ON BLPS MODULATE THEIR INTERACTION WITH AB. THESE STUDIES WILL PROVIDE A DETAILED MOLECULAR MAP OF BLP METABOLISM IN THE CNS WHICH CAN BE LEVERAGED FOR THE DEVELOPMENT OF TARGETED THERAPEUTIC APPROACHES TO TREAT AND PREVENT AD.

Posted 7/2/24, 12:00 AM